Abstract:Chemotherapy (Ctx) and/or radiotherapy (Rtx) are effective in the treatment of Hodgkin's disease (HD) but potentially involve late toxicities, including nephrotoxic side effects. Therefore a follow-up study has been performed to screen patients for late signs of an impaired tubular or glomerular function and to correlate data of renal function with type of therapy and cumulative doses of cytotoxic agents applied. 81 patients in complete remission for at least 2 years and a median follow-up of 96 (39-304) months, and 53 controls were examined. Clinical routine parameters such as creatinine and electrolytes were determined. A differentiation of proteinuria into the albumin, high molecular weight (HMW) and low molecular weight (LMW) fractions made it possible to assess glomerular and tubular function based on the LMW/HMW ratio. The structural protein fibronectin served as an additional, sensitive marker of glomerular integrity. Routine parameters of kidney function did not show any signs of late nephrotoxicity. However, patients treated for HD had a higher ratio of LMW/HMW in comparison to the group of healthy volunteers (p < 0.01), indicating subclinical tubular renal damage. When the cutoff for tubular damage was defined as LMW/HMW > 1.5, 50% of the patients treated with combined modality, and 42 and 37% of the patients with Ctx or Rtx alone had subclinical tubular alterations, respectively. A tendency towards a higher prevalence of subclinical tubular changes was observed in patients with higher cumulative doses of methotrexate or ifosfamide and in patients with combined Ctx and Rtx with radiation fields involving the renal area. Changes in glomerular function were not observed. It is concluded that treatment of HD is not associated with clinically apparent long-term impairment of renal function but can lead to subclinical alterations. Further clinical implications of these subclinical tubular alterations cannot be assessed at present. A differentiation of proteinuria does not have to be performed routinely but might be useful in the follow-up of selected patients with an increased risk.

Treatment of Hodgkin’s Disease with Chemotherapy Based-Regimens: Long-term Follow-Up Results with 295 Patients

Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study.

High-dose chemotherapy followed by autologous stem cell transplantation for patients with refractory/relapsed classical Hodgkin lymphoma: a single center experience from China

High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors

Clinical Study of High Dose Chemotherapy Combined with G-CSF Treating Refractory or Relapsed Non-Hodgkin's Lymphoma

Comparison of preliminary results of involved-field with extended field radiotherapy combined with chemotherapy for early stage Hodgkin's disease]

Evaluation of late nephrotoxicity in long-term survivors of Hodgkin's disease

High-dose chemotherapy following autologous hematopoietic stem cell transplantation for lymphoma:a clinical study

High-Intensity Chemotherapy is Associated with Better Prognosis in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma: A 10-Year Single-Center Retrospective Cohort Study

Retrospective study of 56 cases with Hodgkin lymphoma

Clinic study progress of Hodgkin lymphoma in children and adolescents

Diagnostic and therapeutic developments in classical Hodgkin's lymphoma

Survival analysis and prognostic factors in 115 patients with advanced Hodgkin's lymphoma

Efifcacy of the consolidation chemotherapy after autologous stem cell transplantation in refractory/relapse lymphoma

Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas

Late Effects of Modern Therapy for Hodgkin Lymphoma

Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?

Clinical Features and Prognosis Analysis of Hodgkin Lymphoma: A Multicenter Retrospective Study over A Decade of Patients in China

[Clinical Report on Protocol HL-98 for Childhood Hodgkin's Lymphoma].

Hodgkin Lymphoma on Hemodialysis: A Review of Treatment and Recommendations

The Superiority of Haploidentical Related Stem Cell Transplantation over Chemotherapy Alone As Postremission Treatment for Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in First Complete Remission.